Sarepta therapeutics' srp-9001 shows sustained functional improvements in multiple studies of patients with duchenne

Cambridge, mass., oct. 11, 2021 (globe newswire) -- sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today shared new analyses and functional data from its srp-9001 (raavrh74.mhck7.micro-dystrophin) development program and details of study srp-9001-301, known as embark, its global pivotal phase 3 trial of srp-9001 for the treatment of duchenne muscular dystrophy. srp-9001, being developed in partnership with roche, is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.
SRPT Ratings Summary
SRPT Quant Ranking